This work highlights a microRNA replacement therapy as a therapeutic option for tendon injury.
microRNA29a treatment improves early tendon injury

Introduction
Dysregulated tissue repair and inflammation characterize many musculoskeletal pathologies, including tendon disorders in both human and equine practice [1] [2] [3] [4] . Tendon injuries remain a significant problem in equine practice comprising the most common musculoskeletal injury in racehorses.
Injury to the SDFT, most often involving the metacarpal segment of the forelimb tendon, is one of the most frequent causes of lameness of athletic horses internationally with a reported frequency of 10-30% 5, 6 .
The immune system plays a crucial role in the regulation of tissue remodelling by coordinating complex signalling networks that facilitate transcriptional regulation of extracellular matrix (ECM) components as an adaptive response to environmental cues. Inflammatory mediators are considered crucial to the onset and perpetuation of tendinopathy [7] [8] [9] .
Expression of various cytokines has been demonstrated in inflammatory cell
lineages and tenocytes, suggesting that both infiltrating and resident populations participate in pathology [10] [11] [12] . Additionally, evidence suggests a balance exists between pro inflammatory and pro resolving mediators that may ultimately define the extent to which equine tendinopathy develops and subsequently repairs 13, 14 .
Recent work has identified the importance of tissue microenvironments and the interaction immune mediators in inflammatory/ stromal cell crosstalk 15 . MicroRNAs (miRNAs) are small, non-coding RNAs that suppress gene expression at the post-transcriptional level by inhibiting translation and/or inducing mRNA degradation 16 . A single miRNA can regulate the expression of multiple target mRNAs through sequence binding. Emerging studies highlight miRNAs as key epigenetic regulators of integrated mammalian cell functions 17, 18 . Specific miRNAs have emerged that particularly regulate cytokine networks while orchestrating proliferation and differentiation of stromal lineages that determine ECM composition 19 . miRNAs have provoked extensive interest as regulators of musculoskeletal diseases, although their precise contributions to complex disease pathways remains uncertain 20 . miR-210 has been reported as a crucial regulator of angiogenesis 21 , a key factor in tendon disease, and it accelerated healing of tendon in an Achilles tendon rodent injury model 22 while additionally causing upregulation of vascular endothelial factor, fibroblast growth factor and type I collagen in the same model system. miRNAs designed and engineered according to genetic sequences of transforming growth factor β1 (TGFβ1) and injected in the chicken tendon injury model achieved downregulation of TGFβ1 expression in vitro and in vivo 23 . Some compounds can regulate endogenous miRNA expression, which may confer therapeutic value. One such study demonstrated that miR29b mediated chitosan-induced prevention of tendon adhesion after rodent Achilles tendon injury surgery by regulating the TGFβ1-Smad3 pathway 24 .
We have previously demonstrated a functional role for miR29a as a post-transcriptional regulator of collagen in murine and human tendon injury 25 .
Given the translational potential we designed a randomized blinded trial to evaluate the potential for miR29a replacement therapy as a therapeutic option to treat tendinopathy utilising an equine collagenase model considered analogous to human tendon disease.
Results
miR29a expression in equine tendinopathy model
We found that miR29a was significantly (p<0.01) downregulated throughout the time course of the induced tendinopathy model (Figure 1a) . Additionally, we noted a significant differential regulation of collagen 1 and 3 transcripts throughout the time course (Figure 1b &c) . The most notable changes were in collagen 3 transcript early in the model, which was upregulated 80 fold at week 3 and 25 fold at week 5 post induction which was maintained >30 fold at weeks 9 and 17. This was in contrast to Collagen 1 transcripts which were upregulated significantly less (p<0.05) at early time points (13 fold at 3 weeks, 9 fold at 5 weeks, p<0.05 versus collagen 3 transcript) which was reversed at weeks 9 (26 fold) and 17 (24 fold).
Regulation of collagen expression by miR29a is conserved in equine tenocytes
Sequence analysis revealed that the miR29a binding sites in collagen 1 and 3 transcripts previously described in humans and mice are conserved in horses ( Figures 1 d-e) . To confirm the activities of these predicted miR29a binding sites a series of luciferase reporter constructs containing wild-type and mutated miR29a-bindings sites were made. Over-expression of miR29a decreased luciferase activity in HEK cells transfected with in wild-type but not mutated plasmids demonstrating that both col1a1 and col3a1 are bone fide miR29a targets ( Figure 1 f-g ). To test whether miR29a indeed regulates the levels of candidate target mRNAs in disease-relevant cells, we transfected primary equine tenocytes with miR29a mimic. miR29a manipulation selectively regulated collagen 3 (p<0.01) but not collagen 1 mRNA (Figure 2 a-b). This in is keeping with our previous observations in human tenocytes which showed that miR29a binding sites are excised from collagen 1 transcripts due to the use of an alternative proximal polyadenylation signal 25 .
Comparison of the polyA sites in both col1a1 and col3a1 showed that the polyadenylation signals and the sequences that flank them are identical in other mammalian species including horses and dogs, suggesting that this alternative polyadenylation is conserved in these species (Figure 2 c-f ). To test this, the 3' ends of collagen1 and 3 transcripts were characterised using 3'RACE. Sequence analysis showed that both collagen1 and 3 utilised the same conserved polyadenylation signals found in the corresponding human transcripts ( Figure 2 g-h) . Together these results support the idea of common molecular pathogenic process driven by the loss of miR29a in the development of tendinopathy in human and horses. This finding raises the possibility that re-introduction of miR29a could have significant therapeutic benefit in the healing of tendon lesions.
miR29a treatment improves early tendon healing
The study consisted of two randomly assigned groups: group A (miRNA29a mimic; n =9 ; 5 male, 4 female; miRNA29a) and group B (placebo treated tendons; n = 8; 5 male, 3 female; CONT) with the study timeline detailed in 
Discussion
The molecular processes underpinning the development of collagen 3 over-production seen in tendinopathy have been evolutionarily conserved in mammalian species demonstrating their biological importance. Here we showed that the injury-induced loss of miR29a from tenocytes previously reported in humans also occurs in collagenase-induced tendinopathy in horses and that this inversely correlates with collagen 3 expression. We have demonstrated that as is the case in humans, miR29a has the potential to target both collagen 1 and 3. Despite this, only collagen 3 expression is decreased by the miR29a overexpression in equine tenocytes. A detailed characterisation of col1a1 and col3a1 transcripts reveals that col1a1 utilises an alternative polyA signal that truncates its 3'UTR with the loss of all three miR29 binding sites. This means that in equine tenocytes only collagen 3 is regulated by miR29a, a situation that mirrors that previously described in humans. These findings raised the possibility that re-introduction of miR29a
into the tendinopathic environment could reduce collagen 3 production leading to improved tendon healing. To test this, we designed a blinded, placebocontrolled, experimental trial an equine model that revealed clinically relevant improvement in the healing of earlt tendon injury after intralesional injection of miR29a.
Recent studies highlight miRNAs as key regulators of leukocyte function and differentiation of stromal cells that determine extracellular matrix composition 20, 26, 27 . Our data demonstrate a functional role for miR29a as a post-transcriptional regulator of collagen in equine tendon injury. Despite its many similarities, the collagenase model of tendon injury does not totally mimic the insidious and degenerate etiopathogenesis of many forms of naturally occurring tendon injury in man. However, the clinical relevance of this model to the final acute disruption after months or years of chronic tendon injury, is supported by the evaluation of gross, biochemical and histopathological changes, clinical signs, mechanical characteristics, and MRI and ultrasonographic findings following the induction of injury 28, 29 . Additionally, the collagenase model allows the generation of a homogenous tendon lesion in a controlled group of animals and, therefore, improved ability to detect differences between treated and control arms of the study. The reduced expression of miR29a immediately after tendon injury up until 16 weeks post injury induction and concomitant increase in collagen 3:collagen 1 ratio in control animals that we report herein further demonstrates the model molecularly reflects disease in human and in rodent models of tendinopathy 25 .
The regulation of collagens and other extracellular matrices by the miR29 family has been highlighted in several prior studies 17, 25, 30 . Our results now
show that miR-29a acts as an important repressor to regulate collagen expression in equine tendon healing. The molecular understanding of increased collagen 3 deposition resulting in biomechanical inferiority and degeneration has been largely under investigated in equine tendon disease.
While it is likely that miR29a targets other important genes 31, 32 in the multifaceted tendon injury mileu, our data suggest that the miR29a is a critical driver of the collagen post transcriptional regulation resulting in a key collagen switch that remains a major pathological feature of equine tendinopathy.
Novel quantitative biochemical MRI techniques, such as T2 mapping, have
been increasingly evaluated for their demonstrated sensitivity in detection of earlier biochemical changes (i.e. collagen bril structure, orientation, and water content) in various tissues 33, 34 . Thus the variability in T2 mapping of placebo treated tendons as compared to miR-29a treated tendons suggest improved tissue quality, collagen content and collagen orientation due to miR-29a replacement. , similar to the experience in human tendon disease 39 .
Following stem cells in the horse, there is experimental evidence of improved histology 40, 41 and clinical evidence for safety 42 , improved cellularityreduced re-injury rate compared to historical controls 44 . The initial enthusiasm for stem cells in regenerative medicine was one of tissue specific differentiation in that stem cells implanted to a tendon lesion, for example, would engraft, become tenocytes and produce tendon matrix. As both basic science and clinical data accumulates, it appears that stem cell therapy with the mesenchymal stem cell is due to local production of bioactive molecules and immune modulation rather than tissue specific differentiation and longterm engraftment 45 . Herein, we show that local delivery of miR29a is capable of producing comparable and in some cases superior results to PRP or stem cell treatment (similar experimental trials) with regard to lesion size and histological improvement 46, 47 . Our study appears to mirror the concept of earlier lesion resolution and lack of lesion progression at early time points.
This in conjunction with a concurrent tissue molecular phenotype of reduced collagen 3 confirmed macroscopically on T2 mapping provides convincing evidence that a miR manipulation can target both inflammatory/matrix crosstalk in tendon disease with subsequent lesion resolution. miRNAs have several important advantages in that they are bio-developable and comprise known sequences that are often highly conserved among species, both attractive features from a drug development standpoint.
There are limitations inherent in our study. The equine model has the inability to test therapies in a large number of animals, resulting in a study that may be underpowered. This is due to the significant cost of housing, buying and caring for these animals and the strong emotional and ethical considerations in their use and sacrifice 48 . We additionally note that due to logistical and ethical considerations we were unable to completely age and sex match each animal within the treatment and placebo group. As mentioned the collagenase model of tendon injury does not totally mimic the naturally occurring lesion in man. However, the collagenase model allows the generation of a homogenous tendon lesion in a controlled group of animals and, therefore, improved ability to detect differences between treated and control arms of the study. The equine mid-metacarpal SDFT is a large, weight bearing tendon that is easily accessible, is not confined to a synovial sheath, and in the equine athlete is commonly affected by naturally occurring overstretch tendon injury compounded on previous microfiber disruption, similar to tendinopathies of the human Achilles tendon 49, 50 . Finally, we appreciate future studies should be conducted to further elucidate the ideal time of administration of any equine tendinopathy therapy. These studies would contribute to the understanding of when the best therapeutic results are obtained and whether it is feasible to prevent further injury when the therapy is administered to a still-developing injury.
Conclusion
The present study demonstrated that a microRNA therapy had a favourable action in the treatment of tendinopathy by the prevention of the lesion progression, improved tendon tissue quality and histopathology comparable to current regenerative therapies. This data supports the mechanism of miRNAmediated modulation of the early pathophysiologic events that facilitate tissue remodeling in tendon after injury and provides proof of principle that a locally delivered miR29a therapy can improve early tendon healing. 
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Methods
Equine model of tendinopathy Animals
The data generated in Figures 1 & 2 represent historical RNA tissue samples from a previously published model 41 and were utilized in the pursuit of RRR.
Eight adult female Thoroughbred (n = 7) or Thoroughbred cross (n = 1)
horses, ranging in age from three to seven years, without clinical or ultrasonographic evidence of tendon injury were used. All horses had undergone rigorous athletic training prior to inclusion in the study. Horses were housed separately, in box stalls, and allowed to acclimate to the environment for ≥2 weeks prior to study initiation. These animals then underwent the tendon injury model as described below.
For the randomised section of the trial seventeen adult Quarter Horse-type horses, ranging in age from two to seven years, without clinical or ultrasonographic evidence of tendon injury were used. The sample size was based on the first authors previously published studies utilizing the collagenase model 41, 51 which showed the largest group should have 8 horses to show statistically differences regarding tissue architecture, tendon size, tendon lesion size, and tendon linear fibre pattern. Horses were housed separately, in box stalls, and allowed to acclimate to the environment for ≥2 weeks prior to study initiation. All invasive procedures were performed by an experienced board certified veterinary surgeon (A.E.W). This study was The needle was directed from palmarolateral to dorsomedial.
Study design
The study consisted of two randomly assigned groups: group A (miRNA 29a mimic; n =9 ; 5 male, 4 female; miRNA29a) and group B (placebo treated tendons; n = 8; 4 male, 4 female; CONT). One week after tendon injury by collagenase injection, treatment injections were performed. A subset of animals were euthanized, and tissues were collected at two, four and sixteen weeks. Other than an on-site control officer, all investigators were blinded to treatment group identification until the study was completed and all assays were performed. Treatment group (A or B) was revealed for statistical analysis. Once all analyses were completed, treatment group identification (miRNA29a or CONT) was disclosed.
None of the horses had been previously athletically trained. All horses had been housed at pasture in a group setting until 2 weeks prior to the start of the study, at which point they were housed individually in box stalls until study termination. Eight weeks post treatment injection horses began daily in-hand walking exercise for 5 minutes each day, which was increased to 10 minutes a day for weeks 12-16. There were pre-existing musculoskeletal abnormalities in 2 horses: one horse (mir29a group, 16 week horse) had a mild flexural limb deformity (club foot) and one horse had delayed release of the patella (control group, 16 week horse). One horse (mir29a group,16 week horse) got loose from her handler during the 8 th week post-treatment injection and galloped free for 3 minutes. Other than one horse that was treated for colic prior to study initiation (mir29a group, week 4), none of the horses had a history of prior diseases or treatments other than castration, none required treatment for other diseases or injuries during the study and there was no evidence of prior or concomitant diseases during post mortem exam in any of the horses. The age, sex and weight of each animal is given in Table 2 .
Ultrasound
Ultrasound examinations were performed prior to admission to the study The LCSA as a percentage of TCSA was calculated for relative lesion crosssectional area (RLCSA). Tendons were also scored as having a normal shape (yes/no) and overlying subcutaneous thickening (yes/no).
Magnetic resonance imaging
Magnetic resonance imaging was performed at two, four, six, eight, twelve and sixteen weeks after treatment injection using a 3.0 Tesla MRI system 
Equine tendon explants
To establish tendon explant cultures, the superficial digital flexor tendon was aseptically excised from the midmetacarpal region of both forelimbs of 3 horses (aged 2 to 5 years) without evidence or history of tendon injury; the horses were euthanized for reasons unrelated to the study. Tendons were determined to be normal on the basis of findings via palpation, gross examination, and later dissection for explant culture. Following collection, the tendon segments were maintained in culture medium during the removal of the paratenon. The tendon segments were then sectioned into 5 X 5 X 4-mm blocks and evenly distributed in 12-well plates for explant culture of tenocytes.
Segments were maintained for 6 days at 37 degrees C, 5% CO 2 and 70% humidity in complete medium (penicillin [50 U/mL]; streptomycin [50 µg/mL]; ascorbic acid [100 µg/mL]; and 2% fetal bovine serum) to allow explant culture of tenocytes. After 6 days, each explant was divided, and a portion was snap-frozen in liquid nitrogen and pulverized for RNA isolation with a phenol-guanidine isothiocyanate reagent. A cross-sectional edge was fixed in 4% paraformaldehyde, embedded in paraffin, and sectioned for H&E staining.
Equine tenocytes were transfected with Hsa-miR-29a-3p and miRIDIAN microRNA Negative Control #1 miRNA mimics using Dharmafect 3 (Dharmacon). Transfection efficiency was assessed using miRIDIAN™mimic Transfection control Dy-547 (Dharmacon). We determined the transfection efficiency using a fluorescently labelled miR29a mimic. This was performed initially in cultured human tenocytes where the uptake of labelled miR29a was monitored by fluorescent microscopy. Additionally, we assessed uptake of fluorescent miR29a when injected directly into the murine patellar tendon. In both cases miR29a was readily taken up by tenocytes with transfection efficiency >85%.
RNA and DNA isolation and qPCR
The cells isolated from experiments and freezer mill pulverized tendon samples from the in vivo trial were placed in Trizol before mRNA extraction.
QIAgen mini columns (Qiagen) were used for the RNA clean-up with an incorporated on column DNAse step as per the manufacturer's instructions. Expressions of U6B small nuclear RNA or β-actin were used as endogenous controls.
Luciferase assay
Conserved miR29a binding sites in the 3'UTRs of equine col1a1 and col3a1
were identified using TargetScan. The regions corresponding to these sites were synthesised as G-blocks (Integrated DNA Technologies, Belgium) and inserted downstream of the luciferase ORF in pmiRGLO (Promega) using
Gibson Assembly (New England Biolabs). The equivalent regions in which the seed regions of predicted miR29a binding sites were deleted were created in parallel. Plasmids were transfected into HEK293 cells along with miR29a or scrambled control mimics (Thermofisher) using Attractene (Qiagen).
Luciferase activities were measured using Dual-Glo luciferase assay (Promega). 
